Research

  • UK trial to assess AI effectiveness across all patient groups

    An east midlands NHS trust is carrying out the first UK evaluation of the safety and effectiveness of using AI software across different patient groups. University Hospitals of Leicester NHS Trust (UHL) is working with specialist AI evaluation company Aival to evaluate the performance of a system which currently supports clinicians when viewing chest X-rays. [...]

  • Researchers develop first accurate blood test for chronic fatigue syndrome

    Scientists say they have developed the first blood test to diagnose chronic fatigue syndrome, though experts warn further studies are needed. The test could change how doctors identify myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) – a debilitating illness marked by extreme tiredness not eased by rest. There is currently no diagnostic test, and many patients face [...]

  • Ethics, regulation and the new frontier of longevity: The leadership challenge

    Odgers’ Chris Hamilton and Mike Drew explain why ethics and regulation are becoming defining challenge for longevity executives As the longevity sector races forward, armed with breakthroughs in cellular reprogramming, gene therapies, and AI-driven diagnostics, one reality is becoming clear: scientific innovation alone is no longer enough. Ethical integrity and regulatory fluency are fast becoming [...]

  • Research reveals limitations of blood sugar trackers

    Blood sugar tracking devices may not give accurate readings for people without diabetes, new research suggests. Continuous glucose monitors (CGMs) – small wearable devices fitted to the arm or abdomen – send real-time blood sugar data to an app, showing how glucose levels rise and fall throughout the day. Researchers analysed CGM data from 972 [...]

  • Data driven simulation model could help combat the US opioid crisis

    A team of scientists have developed a data-driven simulation model designed to help policymakers better understand and address the United States' opioid crisis. Researchers report that the model, known as SOURCE (Simulation of Opioid Use, Response, Consequences, and Effects), presents the most detailed model to date of the crisis. It does that by capturing how [...]

  • Building trust, driving adoption: Evidence-led marketing

    By Jasmin Hounsell, co-founder of Evolene Ltd. After device development and regulatory clearance, it feels like it should be an easier ride for medical device developers. However, adoption and implementation are the next big hurdles to overcome. Clinicians are highly educated, meaning that communication needs to both inform and build trust – they will not [...]

  • AI-powered test accurately screens hearing at home without clinical supervision

    An AI-powered hearing test is reliably able to check your hearing on a computer or smart phone without clinical supervision according to a study The high-tech hearing tests, they say, can efficiently understand human speech from the comfort of your own home, rather than at a hospital clinic, by using AI to screen out background [...]

  • Skin sensing technology could transform eczema and psoriasis treatment

    An innovative technology developed by researchers in the UK has received over £475,000 in funding to revolutionise how eczema is diagnosed and treated, potentially ending years of suffering for millions of patients across the UK. The innovative vibroacoustic sensor, which measures material changes in each layer of skin using small vibrations on the surface, has [...]

  • University spin-out raises £2m for gene-editing tool

    A UK company that has developed a novel gene-editing tool has raised £2m to expand its commercial work developing bacteria strains and adapt its tool for use with human and animal cells. Forge Genetics, a spin-out from the University of Nottingham, has secured funding from the Midlands Engine Investment Fund II, through its appointed fund [...]

  • Amorphical announces positive interim results from ongoing Crohn’s trial

    Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, has announced positive interim results from its ongoing open-label clinical trial evaluating its investigational therapy for the treatment of moderate-to-severe Crohn’s disease. The data suggests that the investigational therapy, when added to best available therapy, supports meaningful clinical improvement and remission. The drug has been [...]